Gilead Acquisition Of Cell Design: The Next Logical Step

 
• By Joseph Haas

Already partnered with Kite to apply two technology platforms to CAR-T candidates, Cell Design adds to Gilead's immuno-oncology expertise. Analysts expect more add-ons for Gilead's increasing IO focus.

Handshake of businessmen

More from Immuno-oncology

More from Anticancer